Literature DB >> 22855159

Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA.

A Deezagi1, S Ansari-Majd, N Vaseli-Hagh.   

Abstract

INTRODUCTION: Vascular endothelial growth factor (VEGF) regulates several cell functions including; proliferation, differentiation, permeability, vascular tone, and the production of vasoactive molecules. The purpose of this study was to evaluate the potency of specific short-interfering RNA (siRNA) to suppress human VEGF expression by siRNA and investigate the effects of VEGF down-regulation on the cell proliferation and apoptosis of the human prostate cancer cell lines DU-145.
METHODS: Transfection was performed using X-tremeGENE siRNA transfection reagent. At different time intervals, transfected cells were harvested and total RNA was extracted for RT-PCR. The VEGF content in supernatants were measured by ELISA. Inhibition of cell growth by hVEGF-siRNA was measured by using cell proliferation ELISA BrdU assay. Apoptotic cells were evaluated by using annexin-V-FITC apoptotic detection method.
RESULTS: Transfection of hVEGF-siRNA resulted in statistically significant inhibition of hVEGF-mRNA that in turn caused a marked reduction in the expression of hVEGF. The cell growth was assessed every 24 h for 4 days after siRNA treatment resulted in a marked inhibition of cell proliferation as compared to scramble siRNA. The results of apoptosis showed that approximately 15 % of the cells treated with control-siRNA manifested evident apoptotic changes after 24 hpt, whereas DU-145 cells treated with hVEGF-siRNA significantly were positive, that is to say, 53 % at 72 hpt 23.9 ± 2.78 % (P < 0.001) and 13 ± 1.57 % at 96 hpt.
CONCLUSION: Our findings indicate that siRNA are effective in eliciting the RNAi pathway in cancerous cells and that specific siRNA efficiently down-regulate VEGF expression. They could decrease VEGF production and induce apoptosis, which may also be linked to the inhibition of cancerous cell proliferation. Therefore, it can be concluded that siRNA-mediated suppression of VEGF represents a powerful tool against prostate cancer cell proliferation. VEGF down-regulation exerts a direct anti-apoptotic function in the DU-145 cell lines and promises the development of drugs for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855159     DOI: 10.1007/s12094-012-0868-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  42 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  siRNA targeting Livin decreases tumor in a xenograft model for colon cancer.

Authors:  Bo-Young Oh; Ryung-Ah Lee; Kwang Ho Kim
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

Review 3.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

4.  Blocking effects of siRNA on VEGF expression in human colorectal cancer cells.

Authors:  Yu Yin; Li-Yu Cao; Wen-Qing Wu; Hao Li; Yan Jiang; Hong-Fu Zhang
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

Review 5.  Therapies directed at vascular endothelial growth factor.

Authors:  Paul W Manley; Georg Martiny-Baron; Jean-Marc Schlaeppi; Jeanette M Wood
Journal:  Expert Opin Investig Drugs       Date:  2002-12       Impact factor: 6.206

6.  Expression of vascular endothelial growth factor receptors in human prostate cancer.

Authors:  F A Ferrer; L J Miller; R Lindquist; P Kowalczyk; V P Laudone; P C Albertsen; D L Kreutzer
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

Review 7.  Therapeutic potential of RNA interference against cancer.

Authors:  Fumitaka Takeshita; Takahiro Ochiya
Journal:  Cancer Sci       Date:  2006-08       Impact factor: 6.716

8.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

Review 9.  The role of vascular endothelial growth factor in kidney and prostate cancer.

Authors:  Nicolas Barry Delongchamps; Michaël Peyromaure
Journal:  Can J Urol       Date:  2007-10       Impact factor: 1.344

Review 10.  Vascular endothelial growth factor: basic science and clinical progress.

Authors:  Napoleone Ferrara
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

View more
  6 in total

1.  Antiproliferative effect of a synthetic aptamer mimicking androgen response elements in the LNCaP cell line.

Authors:  S Kouhpayeh; A R Einizadeh; Z Hejazi; M Boshtam; L Shariati; M Mirian; L Darzi; M Sojoudi; H Khanahmad; A Rezaei
Journal:  Cancer Gene Ther       Date:  2016-07-01       Impact factor: 5.987

2.  A prostate-specific antigen-dependent fusion polypeptide inhibits growth of prostate cancer cells in vitro and in vivo.

Authors:  Xiang Zhang; Yueyun Ma; Hua Wei; Bin Li; Fengjing Xiao; Jing Yang; Qiaohong Yue; Angang Yang; Xiaoke Hao
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

3.  Prostaglandin F-2α Stimulates The Secretion of Vascular Endothelial Growth Factor and Induces Cell Proliferation and Migration of Adipose Tissue Derived Mesenchymal Stem Cells.

Authors:  Abdolkhaleg Deezagi; Samira Shomali
Journal:  Cell J       Date:  2018-03-18       Impact factor: 2.479

4.  Downregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells.

Authors:  Doan Chinh Chung; Le Thanh Long; Hoang Nghia Son; Le Tri Bao; Do Minh Si; Le Van Dong
Journal:  Cell J       Date:  2015-07-11       Impact factor: 2.479

5.  Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells.

Authors:  Chung Chinh Doan; Long Thanh Le; Son Nghia Hoang; Si Minh Do; Dong Van Le
Journal:  Biol Res       Date:  2014-12-15       Impact factor: 5.612

6.  A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.

Authors:  Yu Zou; Chuan-Gen Guo; Zheng-Gang Yang; Jun-Hui Sun; Min-Ming Zhang; Cai-Yun Fu
Journal:  Drug Des Devel Ther       Date:  2016-03-24       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.